In fact, it was recently reported that the synergistic activity of the IDH1 inhibitor BAY1436032 with AZA in AML with IDH1 mutations enhances anti-leukemia activity by co-targeting metabolism and methylation [71]. The gene discussed is IDH1; the disease is acute myeloid leukemia.